Trial Profile
The use of bezafibrate and medroxyprogesterone acetate to potentiate the therapeutic effects of retinoids in myelodysplasia and acute myeloid leukaemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2005
Price :
$35
*
At a glance
- Drugs Bezafibrate (Primary) ; Medroxyprogesterone (Primary) ; Retinoids
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- Acronyms PORIDIM
- 04 Aug 2005 New trial record.